Acute lymphoblastic leukemia (ALL) in children is now one of the most curable childhood cancers. In high-income countries, around nine in ten children diagnosed today can expect long-term survival, a dramatic change from the era when the disease was almost always fatal. That progress comes from carefully designed chemotherapy protocols, better risk grouping, measurement of residual disease, and newer targeted and immune therapies.
As a clinician in hematologic malignancies, I find that parents want two things from me early on: an honest sense of the odds and an explanation of what treatment will involve. This article covers both.
What Is Acute Lymphoblastic Leukemia in Children?
ALL is a cancer of the blood and bone marrow in which immature lymphocytes, called lymphoblasts, multiply uncontrollably. They crowd the bone marrow and prevent it from making enough normal red cells, white cells, and platelets.
ALL is the most common of the different types of childhood leukemia, accounting for roughly three-quarters of cases, and it is the most common cancer in children overall. It peaks between about two and five years of age. Most childhood cases are the B-cell form, known as B-cell ALL; a smaller share are T-cell ALL, which is more common in older boys and adolescents.
Causes and risk factors
The cause is unknown in most children. ALL arises from genetic changes acquired in a developing lymphocyte, not usually from anything inherited or anything the family did. Children with Down syndrome and some rare inherited syndromes have a higher risk, and high-dose radiation exposure is an established risk factor. Other environmental exposures have been studied extensively without a clear causal link.
Signs and Symptoms Parents Notice
The signs of leukemia in children are often nonspecific and can resemble common viral illnesses. What stands out is persistence, or several symptoms appearing together.
- Tiredness and pallor from anemia.
- Repeated fevers or infections that are slow to settle.
- Easy bruising, nosebleeds, or pinpoint red spots caused by low platelets, sometimes in unusual places such as the back, as described in our article on leukemia bruises on the spine in children.
- Bone or leg pain, limping, or refusing to walk.
- Swollen glands and a swollen tummy from an enlarged liver or spleen.
How Childhood ALL Is Diagnosed
Diagnosis begins with a physical examination and a complete blood count, which often shows anemia, low platelets, and an abnormal white cell count with blasts on the blood film. The definitive test is a bone marrow aspiration and biopsy, usually done under sedation or general anesthesia in children.
The marrow sample undergoes flow cytometry to confirm B-cell or T-cell ALL, and cytogenetic and molecular testing to identify genetic features that strongly influence prognosis. A lumbar puncture checks whether leukemia cells are present in the spinal fluid.
Survival Rates and What Shapes Prognosis
Survival figures describe groups, not individual children, and they reflect treatment given several years ago. With that caveat, childhood ALL survival has risen steadily for decades, and the large majority of children now become long-term survivors. For comparison with other age groups, see our broader overview of the acute lymphoblastic leukemia survival rate, which is lower in adults.
Doctors assign each child to a risk group using well-established factors:
| Factor | More favorable | Less favorable |
|---|---|---|
| Age at diagnosis | 1 to 9 years | Under 1 year, or 10 years and older |
| White cell count at diagnosis | Below 50,000 per microliter | 50,000 per microliter or higher |
| Cell type | B-cell ALL | T-cell ALL (historically; now treated with intensified therapy) |
| Genetics | High hyperdiploidy, ETV6-RUNX1 fusion | KMT2A rearrangement, hypodiploidy, Philadelphia chromosome |
| Response to treatment | MRD negative after induction | Persistent MRD |
| Spinal fluid involvement | None at diagnosis | Leukemia cells present |
Of these, response to early treatment is among the most powerful predictors, which is why modern protocols measure it so carefully.
How Childhood ALL Is Treated
Treatment usually lasts about two to three years and is divided into phases.
- Induction (about four to five weeks): chemotherapy such as vincristine, a corticosteroid, and asparaginase, sometimes with an anthracycline, aiming for remission.
- Consolidation and intensification (several months): further combination chemotherapy to eliminate remaining leukemia.
- Central nervous system therapy: chemotherapy injected into the spinal fluid throughout treatment to prevent relapse in the brain.
- Maintenance (the longest phase): daily and weekly oral chemotherapy with periodic checkups, which most children receive at home while attending school.
Families can read more about the whole journey, including supportive care, in our childhood leukemia overview.
Advances in Treatment
Several developments explain why outcomes keep improving:
- Minimal residual disease (MRD) testing: highly sensitive tests detect leukemia cells invisible under the microscope. Children with no detectable MRD can often receive less intensive treatment, while those with persistent MRD receive more.
- Genetic risk stratification: identifying subtypes at diagnosis lets treatment be matched to the biology of the leukemia.
- Tyrosine kinase inhibitors: drugs such as imatinib and dasatinib, added to chemotherapy, have greatly improved outcomes in Philadelphia chromosome-positive ALL.
- Immunotherapy: blinatumomab, an antibody that links T cells to leukemia cells, and inotuzumab ozogamicin are used for relapsed or resistant B-cell ALL, and increasingly earlier in treatment.
- CAR T-cell therapy: a child’s own T cells are engineered to attack B-cell ALL, offering a real option for disease that has relapsed or failed to respond.
- Better supportive care: improved infection prevention, transfusion support, and management of side effects have reduced treatment-related deaths.
Frequently Asked Questions
Is childhood ALL curable?
Yes. Most children with ALL are cured with current treatment. Children who relapse still have effective options, including immunotherapy, CAR T-cells, and stem cell transplant.
What does “five-year survival” mean?
It is the proportion of children alive five years after diagnosis. In childhood ALL, most relapses happen within the first few years, so children who remain in remission well beyond the end of treatment are very likely cured.
Will my child be able to go to school during treatment?
During induction and intensive phases, school attendance is usually limited because of infection risk. During maintenance, most children return to school and many normal activities.
Are there long-term effects?
Some survivors experience late effects such as reduced bone density, heart effects from anthracyclines, or learning difficulties. For this reason, children are followed in long-term survivorship clinics after treatment ends.
Key Takeaways
- ALL is the most common childhood cancer and one of the most curable.
- Prognosis depends on age, white cell count, genetics, and especially early treatment response.
- Treatment lasts about two to three years across induction, consolidation, CNS therapy, and maintenance.
- MRD-guided therapy, targeted drugs, immunotherapy, and CAR T-cells continue to raise survival.
